Malignant Mixed Müllerian Tumors (MMMT) also referred to as carcinosarcomas are very rare and extremely aggressive tumors of the uterine corpus accounting for less than 1% of all gynecologic malignancies, 2-5% of all uterine malignancies and more than 15% of all uterine cancer associated deaths [1]. They occur almost exclusively in post-menopausal women, but have been reported in premenopausal women as well, including young girls [2]. Carcinosarcomas have poor prognostic outcome, regardless of stage at diagnosis. The five-year survival rate ranges between 5% and 40% for patients with tumors of all stages [2-5] and does not improve significantly even with the introduction of increasingly aggressive adjuvant therapies.